Cotoretigene toliparvovec

利哌考瑞基

Report date: 2023/10/26 16:40:18

Base Information

Drug NameCotoretigene toliparvovec
Drug Alias NameAAV-RPGRAAV-XLRPGR gene therapyNSR AAV-RPGRAAV XLRPGRNSR-RPGR +[6] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV8 vector
Mechanisms of ActionRPGR gene transference
TargetsX-linked retinitis pigmentosa GTPase regulator
Therapy Area/IndicationsRetinitis Pigmentosa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Oxford
China Registration ClassN/A

Develop Information

Active CompaniesBiogen IncJohnson & Johnson
Inactive CompaniesN/A
Active IndicationsRetinitis Pigmentosa
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A